Probiotics for treatment and primary prevention of allergic diseases and asthma: looking back and moving forward

Expert Rev Clin Immunol. 2016 Jun;12(6):625-39. doi: 10.1586/1744666X.2016.1147955. Epub 2016 Mar 4.

Abstract

Microbial ecosystems cover the surface of the human body and it is becoming increasingly clear that our modern environment has profound effects on microbial composition and diversity. A dysbiotic gut microbiota has been associated with allergic diseases and asthma in cross-sectional and observational studies. In an attempt to restore this dysbiosis, probiotics have been evaluated in randomized controlled trials. Here, we review treatment and primary prevention studies, recent meta-analyses, and discuss the current understanding of the role of probiotics in this context. Many meta-analyses have shown a moderate benefit of probiotics for eczema prevention, whereas there is less evidence of a benefit for other allergic manifestations. Because of very low quality evidence and heterogeneity between studies, specific advice on the most effective regimens cannot yet be given - not even for eczema prevention. To be able to adopt results into specific recommendations, international expert organizations stress the need for well-designed studies.

Keywords: Diversity; dysbiosis; eczema; gut microbiome; hygiene hypothesis; primary prevention; probiotic.

Publication types

  • Review

MeSH terms

  • Animals
  • Asthma / therapy*
  • Humans
  • Hypersensitivity / therapy*
  • Immunity, Mucosal*
  • Meta-Analysis as Topic
  • Microbiota*
  • Primary Prevention / trends
  • Probiotics / therapeutic use*
  • Randomized Controlled Trials as Topic